Core Viewpoint - Weir Pharmaceutical (603351.SH) has announced that its production and operational conditions have not undergone significant changes, indicating stability in its business environment and market conditions [1] Company Overview - The main business of Weir Pharmaceutical includes the research, production, and sales of synthetic lubricating base oils and pharmaceutical excipients, with projected revenue contributions of 68.95% and 26.12% for the year 2024 respectively [1] Operational Stability - The overall operational situation of the company remains stable, with no major adjustments in market environment or industry policies [1] - There have been no significant fluctuations in production costs or product prices, and internal production and operational order is normal [1]